• Introduction Cancer which is responsible for a million

  2023-08-01

  

  Introduction Cancer, which is responsible for a million deaths each year, is universally feared, and approximately 50% of newly diagnosed cases can be cured [1]. The existing cancer treatments, including surgery, chemotherapy, radiotherapy or a combination of them, are quickly losing efficacy. The

• Aurora A or B selective and pan aurora inhibitors

  2023-08-01

  

  Aurora -A or -B selective and pan-aurora inhibitors have demonstrated different preclinical and clinical therapeutic efficacies [2,[19], [20], [21], [22], [23]]. For example, clinical trials for a pan-Aurora inhibitor VX-680 (developed by Vertex) were halted at phase II for toxicity reasons (one cas

• There is limited information regarding hyperargininemia

  2023-08-01

  

  There is limited information regarding hyperargininemia incidence or prevalence. Reports of incidence vary by an order of magnitude: 0.5 to 5.0 per million [5], [6]. A relatively large U.S. study estimated 1.1 cases per million births [7], but it used an indirect methodology that introduces uncertai

• At Johns Hopkins Aramco Health JHAH we

  2023-08-01

  

  At Johns Hopkins Aramco Health (JHAH), we started an ASP in 2011 with an educational program of physicians and pharmacist. The program was enhanced mid-2012 with the following interventions: a re-designed antibiotic sensitivity report [2], intravenous to oral conversion program, vancomycin pharmacok

• Regarding progression free survival analyzing clinical trial

  2023-08-01

  

  Regarding progression free-survival, analyzing 12 clinical trials, we demonstrated that the use of antiangiogenic treatment results in a statistically longer PFS with a pooled HR of 0.76 (95% CI 0.65–0.89, p high heterogeneity in the effect of antiangiogenic drugs on the hazard risk for progression-

• Dual acting RAAS blockade and neprilysin inhibition

  2023-08-01

  

  Dual-acting RAAS blockade and neprilysin inhibition has been evaluated in several clinical HF trials. In PARADIGM-HF [6,7], LCZ696 was superior to enalapril in reducing mortality and HF hospitalizations in symptomatic patients with HF with reduced EF. Augmented benefits on maladaptive cardiac remode

• br Role of AMPK in inflammation signaling

  2023-08-01

  

  Role of AMPK in inflammation signaling Pro-inflammatory cytokines, such as interleukin (IL)-6 and tumor necrosis factor-α (TNF-α), activate Ikβ kinase (IKKβ), which phosphorylates IκBα, triggering the degradation of proteasomal IκB. This liberates active nuclear factor kB (NF-kB) to translocate i

• Heart failure is a chronic syndrome in which the

  2023-08-01

  

  Heart failure is a chronic syndrome in which the heart is unable of pumping an adequate supply of blood to meet the metabolic requirements of the body or generating the required elevated ventricular filling pressures to maintain output [34]. Despite considerable advances in the treatment of heart fa

• Young et al described the

  2023-08-01

  

  Young et al. [40] described the role of adenine monophosphate-activated protein kinase (AMPK) in the translocation of GLUT4 in the heart. The AMPK is activated during muscle contraction [74] by converting AMP to ATP. The adenosine analog, 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), is a c

• Ozone induced innate inflammatory responses in

  2023-08-01

  

  Ozone-induced innate inflammatory responses in the lung involve neutrophil extravasation through enhanced trans-endothelial migration (Krishna et al., 1997). Catecholamines and glucocorticoids, which are increased by ozone inhalation (Bass et al., 2013, Miller et al., 2015, Miller et al., 2016a, Mil

• The direction of research then turned to investigating

  2023-08-01

  

  The direction of research then turned to investigating the long-term effects of adiponectin on insulin resistance. Adiponectin transgenic mice showed a reduction in insulin resistance and diabetes [5,6], while adiponectin-deficient mice showed mild insulin resistance with glucose intolerance, as wel

• AMPK is a serine threonine protein kinase composed of a

  2023-08-01

  

  AMPK is a serine/threonine protein kinase composed of a catalytic α subunit with the activating phosphorylation site (Thr172) and two regulatory subunits, β and γ. The two AMPK variants, α1 and α2, show different cellular localization in mammalian cells. AMPKα2 is detected in nuclear and non-nuclear

• These results from the present study are

  2023-08-01

  

  These results from the present study are summarized in Table 1. Eight drugs (doxorubicin, epirubicin, daunorubicin, idarubicin, irinotecan, imatinib, sunitinib and gefitinib) inhibited 5-HT-induced 5-HT3A and 5-HT3AB currents; three (irinotecan, topotecan and mitoxantrone) showed different responses

• br Materials and methods br Results The average body

  2023-08-01

  

  Materials and methods Results The average body weights for each group of mice over the course of the study are shown in Fig. 2A. The average body weights of the mice in the saline control group and PACAP group increased slightly during the study. In contrast, starting at day 17, the body weigh

• br A Rs which were cloned and then

  2023-08-01

  

  A3Rs, which were cloned and then pharmacologically identified in the early 1990s, are expressed in multiple organs and peripheral tissues including JNJ-1661010 mg involved in inflammatory responses (Gessi et al., 2008, Borea et al., 2014). While low levels are expressed in the CNS, A3R agonists pr

16058 records 299/1071 page Previous Next First page 上5页 296297298299300 下5页 Last page